The economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in Denmark
CONCLUSION: Achieving early and intensive glycemic control, thereby minimizing therapeutic inertia can lead to substantial savings for the Danish society, ranging between 72 million DKK and 384 million DKK (€9.6 million to €51.4 million) (1 - 7 years of therapeutic inertia).This study highlights that efforts to minimize therapeutic inertia, by securing timely intensification before individual HbA1c targets are exceeded, results in significant long-term cost savings in Denmark.PMID:33729871 | DOI:10.1080/03007995.2021.1904863
Source: Current Medical Research and Opinion - Category: Research Authors: Asger Lindvig Martin Phuc Tran Robert Kidd Christian K Tikkanen Peter Gaede Source Type: research
More News: Denmark Health | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Economics | Endocrinology | Epidemiology | Research | Study | Sweden Health